| Revenue growth | 14% YoY for FY26. |
|---|---|
| Margins | Stable outlook; currently around 32% vs historical 38%. |
| Demand visibility | Steady demand across markets; healthy volume traction. |
| Management confidence | High on long-term growth and execution discipline. |
Growth
Annual revenue grew 14% to ₹11,067 cr; Q4 PAT stood at ₹751 cr.
Outlook
Targeting double-digit revenue growth; ₹2,113 cr CWIP with ₹1,500 cr Kakinada expansion planned.
Risks
Geopolitical tensions in West Asia impacting freight costs and raw material lead times.
Earnings Call filed with BSE, NSE: DIVISLAB. Summary written with AI assistance from the document.
Divi's Laboratories Ltd: key numbers
- Share price
- ₹9,619.50
- Market cap
- ₹2,55,368 Cr
- Revenue (annual)
- ₹10,560 Cr
- Net profit (annual)
- ₹2,568 Cr
- P/E (TTM)
- 87.3×Sector 50.4×
- Promoter holding
- 51.88%+0.00% QoQ
- FII holding
- 20.19%Current quarter
Reference market data from a third-party provider, updated daily. Not a valuation or a recommendation.
More from Divi's Laboratories Ltd
All →Divi's Laboratories Other Announcement
An immediate relative of a Divis Laboratories promoter bought equity shares worth ₹0.58 Crore through a market purchase.
- Value
- ₹0.58 Cr
Divi's Laboratories Other Announcement
Designated Person PRASAD Y.T.S. disclosed the release of two share pledges involving 2,734 equity shares. The combined transaction value of the released pledges is Rs. 2.56 Crore.
- Value
- ₹2.56 Cr
Divi's Laboratories Other Announcement
Designated person PRASAD Y.T.S. sold 6,234 equity shares of Divis Laboratories Ltd for ₹5.84 Crore via market sale.
- Value
- ₹5.84 Cr
Divi's Laboratories Promoter Selling: ₹0.19 Cr
K. Sridevi, an immediate relative, sold 200 equity shares of Divi's Laboratories Ltd via a market sale worth ₹0.19 Crore.
- Value
- ₹0.19 Cr
Divi's Laboratories Other Announcement
K. Sridevi, an immediate relative, sold 200 equity shares of Divi's Laboratories Ltd in a market transaction valued at ₹18.56 Lakh.
- Value
- ₹0.19 Cr
Divi's Laboratories Earnings Call Transcript: Key Takeaways
Divi's Laboratories showcases dominant market positioning in APIs and custom synthesis with ~$1.25B revenue, focusing on volume-led growth across 100+ countries.